Coronary imaging developer Infraredx announced that the first patient has been enrolled in the Providing Regional Observations to Study Predictors of Events in the Coronary Tree (PROSPECT) II trial.
The multicenter, prospective study is designed to assess the ability of intravascular imaging to identify nonflow-obstructing vulnerable plaques, the company said. The first patient was enrolled by Dr. David Erlinge, PhD, one of the study's principal investigators, from Lund University in Sweden.
Infraredx's true vessel characterization (TVC) imaging system will be used to identify lipid-core plaque, a type of fatty coronary artery plaque implicated in most heart attacks. The technology integrates near-infrared spectroscopy (NIRS) with enhanced intravascular ultrasound (IVUS) and is used to guide percutaneous coronary interventions.
Infraredx will provide the primary funding for the study, with additional support from the Medicines Company and Abbott Vascular.
